Singulair gains dual asthma-hayfever indication
pharmafile | March 2, 2005 | News story | Sales and Marketing |
Merck Sharpe & Dohme's blockbuster oral asthma treatment Singulair has received an expanded UK licence for the treatment of adult asthma with co-existing hayfever (seasonal allergic rhinitis).
Singulair can now be used to treat patients with both mild to moderate asthma and the relief of seasonal allergic rhinitis in adult asthma patients in whom the product is indicated.
MSD estimates that three to four million people in the UK suffer from both conditions, which are closely associated but tend to be managed separately.
Singulair received its first UK licence in 1998 and is currently one of MSD's US parent company Merck's four biggest-selling products.
Last year worldwide sales rose to $2.6 billion and Merck expects it to reach $3.2 billion in 2005. The company plans further new indications for Singulair against perennial allergic rhinitis, exercise-induced bronchospasm, acute asthma and respiratory syncytial viral bronchiolitis.